Data from ACRIN-FLT-Breast

ACRIN 6688, a [18F]-fluorothymidine (FLT) imaging study using positron emission tomography (PET), was designed to evaluate the relationship between [18F] FLT uptake parameters and pathologic complete response to neoadjuvant therapy of the primary tumor in patients with locally advanced breast cancer.Participant Eligibility and Enrollment: Criteria for inclusion were patients with pathologically confirmed breast cancer and determined to be a candidate for primary systemic (neoadjuvant) therapy and for whom surgical resection of residual primary tumor following completion of neoadjuvant therapy is planned. The study was open to enrollment from September 2009 to September 2012. Final accrual to the study was 90 patients, of which 80 were included in the analysis.

ACRIN 6688是一项采用正电子发射断层显像（positron emission tomography，PET）的[18F]-氟胸腺嘧啶（[18F]-fluorothymidine，FLT）成像研究，旨在评估局部晚期乳腺癌患者中，[18F]FLT摄取参数与原发肿瘤新辅助治疗后病理完全缓解之间的关联。受试者入选与入组：纳入标准为经病理学确诊的乳腺癌患者，且被判定为适合接受全身原发（新辅助）治疗的候选者，并计划在新辅助治疗完成后对残留原发肿瘤实施手术切除。本研究于2009年9月至2012年9月开放入组，最终共入组90例患者，其中80例被纳入分析。